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Conclusions: The potential of the contrast enhancement 
method in increasing the applicability of markerless lung 
tumour tracking based on kV imaging was demonstrated on 
clinical data. A time-resolved (4D) CT scan can be used 
instead of the breath-hold CT scan available for this study in 
order to improve the robustness in the background 
subtraction operation, especially in case of lower lobe 
tumours for the compensation of diaphragm motion due to 
breathing. 
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Purpose/Objective: The purpose of this study is to evaluate 
the feasibility of markerless tumor detection using sequential 
dual-energy fluoroscopy sequences. As fast-switching kilovolt 
(kV) generators are not readily available, motion artifacts 
due to a time lapse between high and low energy images are 
often a cause for concern. For those kV generators without 
rapid switching, an alternative approach is proposed 
consisting of using sequential (high and low kV) high frame 
rate fluoroscopy sequences, already available in the clinical 
dynamic tracking (DT) workflow of the Vero SBRT system to 
build the hybrid correlation model. 
Materials and Methods: Two sequential 20s (11 Hz) 
fluoroscopy sequences were acquired at the start of one 
fraction for 4 patients treated for primary NSCLC with DT on 
the Vero SBRT system. Two sequences were acquired, using 2 
on-board kV imaging systems located at ± 45° from the MV 
beam axis, at respectively 60 kV (3.2 mAs) and 120 kV (2.0 
mAs). Table 1 shows the kV imager positions, which were 
selected based on marker visibility. Offline, a normalized 
cross-correlation algorithm was applied to anatomically 
match the high (HE) and low energy (LE) images. Per 
breathing phase (inhale, exhale, maximum inhale and 
maximum exhale), the five best matching HE and LE couples 
were extracted for dual energy subtraction. A validation on 
an anthropomorphic phantom with an imposed artificial 
tumor volume was conducted to validate the dual-energy 
approach. A contrast analysis according to gross tumor 
volume (GTV) was conducted between the DE and HE images 
based on contrast to noise ratio. Improved tumor visibility 
was quantified in function of 4 breathing phases using an 
improvement ratio (IR=CNRDE/CNRHE). 
Results: The additional acquisition of a 60 kV fluoroscopy 
sequence enabled an unambiguous approach to dual-energy 
imaging into the clinical workflow. Normalized cross 
correlation for HE-LE fluoroscopy sequence matching resulted 
in a mean correlation coefficient of 0.92 ± 0.18 based on the 
5 best anatomical HE-LE matches per breathing phase. 
Contrast to noise ratio’s (CNR) per patient can be found in 
Table 1. Bone suppression by DE subtraction imaging was 
successful. An example is shown in Figure 1. Based on the 
CNR, with the exception of one imaging angle the DE images 
showed no significantly improved tumor visibility compared 
to the HE images, with an improvement ratio averaged over 
all patients of 1.00 ± 0.50. 
Conclusions: Dual-energy subtraction imaging by sequential 
orthogonal fluoroscopy was shown feasible by implementing 
an additional LE fluoroscopy sequence into the DT workflow. 
However, for most imaging angles, dual-energy images 
showed no significantly improved tumor visibility over HE 
imaging. 
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